PMID- 15644155
OWN - NLM
STAT- MEDLINE
DCOM- 20060324
LR  - 20190922
IS  - 1672-1977 (Print)
IS  - 1672-1977 (Linking)
VI  - 3
IP  - 1
DP  - 2005 Jan
TI  - [Therapeutic effect of Xincang Decoction on chronic airway inflammation in 
      children with bronchial asthma in remission stage].
PG  - 23-7
AB  - OBJECTIVE: To observe the therapeutic effect of Xincang Decoction on chronic 
      airway inflammation in children with asthma in clinical investigation. METHODS: 
      Xincang Decoction was composed of Flos Magnoliae (Xinyi) and Fructus Xanthii 
      (Cangoerzi), the traditional Chinese herbs for expelling wind. Sixty cases of 
      children with bronchial asthma in remission stage were randomly divided into two 
      groups. Thirty cases in the treatment group were treated with Xincang Decoction 
      and the others in the control group were treated with ketotifen fumarate. The 
      therapeutic effects of the two groups were compared, and the peripheral 
      eosinophil (EOS) count, the levels of immunoglobulin E (IgE), interleukin 4 
      (IL-4) and interleukin 5 (IL-5), and the pulmonary functions were observed before 
      and three months after the treatment. RESULTS: After three months treatment, the 
      results showed that the total response rates of the treatment and the control 
      group were 83.3% and 80.0%, respectively, without marked difference (P>0.05). The 
      levels of EOS and IL-5 were obviously decreased after the treatment, and the 
      levels of EOS and IL-5 of the patients in the treatment group were lower than 
      those in the control group (P<0.05). Meanwhile the forced expiratory volume in 
      one second (FEV(1)) was improved after the treatment, and the FEV(1) of the 
      patients in the treatment group was higher than that of the patients in the 
      control group (P<0.05). CONCLUSION: Xincang Decoction can decrease the levels of 
      EOS and IL-5 and improve the pulmonary function in treating chronic airway 
      inflammation in children with bronchial asthma in remission stage.
FAU - Zhu, Hui-Hua
AU  - Zhu HH
AD  - Department of Pediatrics, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 
      200437, China. since1d@yahoo.com.cn
FAU - Chen, Yan-Ping
AU  - Chen YP
FAU - Yu, Jian-Er
AU  - Yu JE
FAU - Wu, Min
AU  - Wu M
FAU - Li, Zhan
AU  - Li Z
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhong Xi Yi Jie He Xue Bao
JT  - Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
JID - 101199657
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Interleukin-5)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Asthmatic Agents/therapeutic use
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Asthma/*drug therapy/etiology
MH  - Bronchitis/complications/drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Eosinophils
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Interleukin-5/blood
MH  - Male
MH  - *Phytotherapy
EDAT- 2005/01/13 09:00
MHDA- 2006/03/25 09:00
CRDT- 2005/01/13 09:00
PHST- 2005/01/13 09:00 [pubmed]
PHST- 2006/03/25 09:00 [medline]
PHST- 2005/01/13 09:00 [entrez]
AID - 324 [pii]
AID - 10.3736/jcim20050108 [doi]
PST - ppublish
SO  - Zhong Xi Yi Jie He Xue Bao. 2005 Jan;3(1):23-7. doi: 10.3736/jcim20050108.